GW Pharmaceuticals Plc (GWPH)

170.88
4.86 2.77
NASDAQ : Health Technology
Prev Close 175.74
Open 175.69
Day Low/High 170.25 / 175.69
52 Wk Low/High 90.14 / 196.00
Volume 287.41K
Avg Volume 388.00K
Exchange NASDAQ
Shares Outstanding 30.72M
Market Cap 5.40B
EPS -10.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
GW Pharmaceuticals Plc Reports Second Quarter 2015 Financial Results And Operational Progress

GW Pharmaceuticals Plc Reports Second Quarter 2015 Financial Results And Operational Progress

Conference Call Today at 8:00 a.m. EDT, 1:00 p.m. BST

Here's What's Driving Biotech

And it's not the favorable macroeconomic climate.

That Was the Week That Was

That Was the Week That Was

Let's review.

Big Pharma and Tobacco Companies Will Benefit From Cannabis Boom

Big Pharma and Tobacco Companies Will Benefit From Cannabis Boom

Christian Hageseth, founder of Green Man Cannabis and author of ‘Big Weed,’ gives a glimpse into the business side of the marijuana world.

Haze May Be Lifting for GW Pharma

This is one hot pot stock.

Nothing 'Healthy' About This Correction

All corrections are unhealthy when they involve earnings.

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

Cramer likes Acadia Pharmaceuticals and prefers Schlumberger over U.S. Silica Holdings.

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

From earnings to activist investors, Cramer said investors need to focus on the good things now happening in the markets.

Jim Cramer -- Buy GW Pharmaceuticals but Only on Pullback

Jim Cramer -- Buy GW Pharmaceuticals but Only on Pullback

TheStreet's Jim Cramer said GW Pharma is producing some important cannabis-based treatments but its stock should be considered a speculative buy.

GW Pharmaceuticals Notes New Epidiolex(R) Data Released By The American Academy Of Neurology

GW Pharmaceuticals Notes New Epidiolex(R) Data Released By The American Academy Of Neurology

More Detailed Poster Presentation Scheduled at AAN Annual Meeting on 22 April 2015

Remarkable Biotech Runs Continue

A Fed-related dip may be your only hope to get in lower.

What Is Wrong With You People?

These companies are doing great -- take some profits!

Buzzkill: Marijuana Stock Frenzy Looks Like It's Totally Crashed

Buzzkill: Marijuana Stock Frenzy Looks Like It's Totally Crashed

Pot-related stocks have gone up in flames over the past year amid legal woes and failure to show any profits.

GW Pharmaceuticals Plc Reports First Quarter 2015 Financial Results And Operational Progress

GW Pharmaceuticals Plc Reports First Quarter 2015 Financial Results And Operational Progress

-Conference Call Today at 8:00 a.m. EST, 1:00 p.m. GMT-

'Mad Money' Lightning Round: I'm in GW Pharmaceuticals for the Long Term

'Mad Money' Lightning Round: I'm in GW Pharmaceuticals for the Long Term

Cramer likes FireEye, does not like Rockwell Medical and is staying away from Ally Financial and Aon.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching earnings from Exxon Mobil, General Motors and Buffalo Wild Wings, among many others.

Where Did the Sellers Go?

But positives could be gone if oil dips to $43.

GW Pharmaceuticals Provides Update On Epidiolex(R) Program In Treatment Resistant Childhood Epilepsies

GW Pharmaceuticals Provides Update On Epidiolex(R) Program In Treatment Resistant Childhood Epilepsies

All Trials on Track or Ahead of Schedule With Phase 3 Data Now Expected by End 2015